Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 3/20 | 0.51 |
| ▸ | PPARG | P37231 | 4/20 | 0.42 |
| ▸ | PPARA | Q07869 | 3/20 | 0.42 |
| ▸ | IDH1 | O75874 | 5/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21045869 | 1.00 | MEN1 (0.54) | MEN1KMT2ALMNAPPARGPPARA | |
| SCHEMBL21045871 | 1.00 | MEN1 (0.54) | MEN1KMT2ALMNAPPARGPPARA | |
| SCHEMBL21045876 | 0.90 | MEN1 (0.48) | MEN1KMT2ALMNAPPARGPPARA | |
| SCHEMBL21045872 | 0.90 | MEN1 (0.48) | MEN1KMT2ALMNAPPARGPPARA | |
| SCHEMBL21045874 | 0.90 | MEN1 (0.48) | MEN1KMT2ALMNAPPARGPPARA | |
| SCHEMBL21045901 | 0.88 | MEN1 (0.46) | MEN1KMT2ALMNAPPARGPPARA | |
| SCHEMBL21045900 | 0.88 | MEN1 (0.46) | MEN1KMT2ALMNAPPARGPPARA | |
| SCHEMBL21045902 | 0.88 | MEN1 (0.46) | MEN1KMT2ALMNAPPARGPPARA | |
| SCHEMBL21045960 | 0.87 | MEN1 (0.46) | MEN1KMT2ALMNAPPARGPPARA | |
| SCHEMBL21045962 | 0.87 | MEN1 (0.46) | MEN1KMT2ALMNAPPARGPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10550084-B2 | Substituted 1-hydroxy-pyridin-2(1H)-ones, and methods of making and using same | ARBUTUS BIOPHARMA CORPORATION (CA) | 2020-02-04 | — | — | US | disclosed |
| US-20190169128-A1 | SUBSTITUTED 1-HYDROXY-PYRIDIN-2(1H)-ONES, AND METHODS OF MAKING AND USING SAME | ARBUTUS BIOPHARMA CORPORATION (CA) | 2019-06-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10550084-B2 | Substituted 1-hydroxy-pyridin-2(1H)-ones, and methods of making and using same | RNASEH1, RNASE1, RNASEL | MEN1 1891/4885KMT2A 1917/4885LMNA 281/4885 |
| US-20190169128-A1 | SUBSTITUTED 1-HYDROXY-PYRIDIN-2(1H)-ONES, AND METHODS OF MAKING AND USING SAME | RNASEH1, RNASE1, RNASEL | MEN1 1891/4885KMT2A 1917/4885LMNA 281/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.